Query 15-11: Intravitreal bevacizumab for retinal conditions: real-world safety assessment


This project was originated with a query by CADTH and funded in June 2016 for one year. The objective of this study is to examine ocular complications of anti-VEGF injections given for neovascular age-related macular degeneration (AMD) and other retinal conditions in population-based cohorts.


In previous analysis, we reported the risk of primary and secondary outcomes in the AMD and the diabetic retinopathy cohorts. These results were presented at the International Conference on Pharmacoepidemiology & Therapeutic Risk Management. During this period, we conducted survival analysis in the other two cohorts, a diabetic macular edema cohort and a retinal neovascularisation cohort, using Cox regression models. Additional analysis was performed to assess the risk of the individual anti-VEGF agents on primary outcome. Full results of these analyses were presented in a separate report submitted July 2017. In the next months, we will conduct additional analysis with the secondary outcome for the four cohorts, as well as analysis with individual outcomes. We will also prepare the first manuscript describing the complete set of results for the AMD cohort.


For more information contact: Autumn Neville. Research Coordinator. autumn.neville@rimuhc.ca   514.934.1934 ext.44844  or  514.699.4828

Comments are closed.